1. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Issue 11 (November 2021) Authors: Diver, Sarah; Khalfaoui, Latifa; Emson, Claire; Wenzel, Sally E; Menzies-Gow, Andrew; Wechsler, Michael E; Johnston, James; Molfino, Nestor; Parnes, Jane R; Megally, Ayman; Colice, Gene; Brightling, Christopher E Journal: Lancet Issue: Volume 9:Issue 11(2021) Page Start: 1299 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗